Advertisement

Imaging of Adrenal Neoplasms

Chapter
Part of the Atlas of Oncology Imaging book series (AOI, volume 1)

Abstract

Lesions of the adrenal glands rarely present clinically and are usually detected as incidental findings on imaging. The incidence of adrenal masses found at computed tomography (CT) or magnetic resonance (MR) imaging of the abdomen has been reported to be 4–6 %, with the overall number of lesions having increased significantly in recent years given the rapid expansion of abdominal imaging in clinical practice. This incidence varies greatly with age: patients between 20 and 29 years of age, for example, have a 0.2 % incidence of adenomas detected on CT, compared with 7–10 % in elderly patients.

Keywords

Adrenal Gland Inferior Vena Cava Adrenal Mass Adrenal Metastasis Adrenal Adenoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. Endocrinol Invest. 2006;29:298–302.PubMedGoogle Scholar
  2. 2.
    Mansmann G, Lau J, Blak E, et al. The clinically inapparent adrenal mass: update in diagnosis and treatment. Endocr Rev. 2004;25:309–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Dunnick NR, Korobkin M. Imaging of adrenal incidentalomas. AJR Am J Roentgenol. 2002;179:559–68.PubMedCrossRefGoogle Scholar
  4. 4.
    Young Jr WF. The incidentally discovered adrenal mass. N Engl J Med. 2007;356:601–10.PubMedCrossRefGoogle Scholar
  5. 5.
    Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16:460–84.PubMedGoogle Scholar
  6. 6.
    Young Jr WF. Management approaches to adrenal incidentalomas: a view from Rochester, Minnesota. Endocrinol Metab Clin North Am. 2000;29:159–85.PubMedCrossRefGoogle Scholar
  7. 7.
    Johnson PT, Horton KM, Fishman EK. Adrenal mass imaging with multidetector CT: pathologic conditions, pearls and pitfalls. Radiographics. 2009;29:1333–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Bülow B, Ahrén B. Swedish research council study group of endocrine abdominal tumours. Adrenal incidentaloma—experience of a standardized diagnostic programme in the Swedish prospective study. J Intern Med. 2002;252:239–46.PubMedCrossRefGoogle Scholar
  9. 9.
    Caplan RH, Strutt PJ, Wickus GG. Subclinical hormone secretion by incidentally discovered adrenal masses. Arch Surg. 1994;129:291–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Reincke M, Nieke J, Krestin GP, et al. Preclinical Cushing’s syndrome in adrenal “incidentalomas”: comparison with adrenal Cushing’s syndrome. J Clin Endocrinol Metab. 1992;75:826–32.PubMedCrossRefGoogle Scholar
  11. 11.
    Bernini GP, Vivaldi MS, Argenio GF, et al. Frequency of pheochromocytoma in adrenal incidentalomas and utility of the glucagon test for the diagnosis. J Endocrinol Invest. 1997;20:65–71.PubMedGoogle Scholar
  12. 12.
    Mannelli M, Colagrande S, Valeri A, Parent G. Incidental and ­metastatic adrenal masses. Semin Oncol. 2010;37:649–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Wooten MD, King DK. Adrenal cortical carcinoma: epidemiology and treatment with mitotane and a review of the literature. Cancer. 1993;72:3145–55.PubMedCrossRefGoogle Scholar
  14. 14.
    Nader S, Hickey RC, Sellin RV, Samaan NA. Adrenal cortical ­carcinoma: a study of 77 cases. Cancer. 1983;52:707–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Luton JP, Cerdas S, Billaud L, et al. Clinical features of ­adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322:1195–201.PubMedCrossRefGoogle Scholar
  16. 16.
    Bharwani N, Rockall A, Sahdev A, et al. Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR Am J Roentgenol. 2011;196:W706–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Willatt JM, Francis IR. Radiologic evaluation of incidentally ­discovered adrenal masses. Am Fam Physician. 2010;81:1361–6.PubMedGoogle Scholar
  18. 18.
    Patnaik MM, Deshpande AK. Diagnosis: Addison’s disease secondary to tuberculosis of the adrenal glands. Clin Med Res. 2008;6:29.PubMedCrossRefGoogle Scholar
  19. 19.
    Frilling A, Tecklenborg K, Weber F, et al. Importance of adrenal incidentaloma in patients with a history of malignancy. Surgery. 2004;136:1289–96.PubMedCrossRefGoogle Scholar
  20. 20.
    Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190:1163–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Bernardino ME, Walther MM, Phillips VM, et al. CT-guided adrenal biopsy: accuracy, safety, and indications. AJR Am J Roentgenol. 1985;144:67–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Francis IR, Smid A, Gross MD, et al. Adrenal masses in oncologic patients: functional and morphologic evaluation. Radiology. 1988;166:353–6.PubMedGoogle Scholar
  23. 23.
    McGahan JP. Adrenal gland: MR imaging. Radiology. 1988;166:284–5.PubMedGoogle Scholar
  24. 24.
    Elsayes KM, Mukundan G, Narra VR, et al. Adrenal masses: MR imaging features with pathologic correlation. Radiographics. 2004;24:S73–86.PubMedCrossRefGoogle Scholar
  25. 25.
    Zornoza J, Bracken R, Wallace S. Radiologic features of adrenal metastases. Urology. 1976;8:295–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Dighe M, Francis IR, Casalino DD, et al. ACR appropriateness ­criteria on obstructive voiding symptoms secondary to prostate ­disease. J Am Coll Radiol. 2010;7:255–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Hedican SP, Marshall FF. Adrenocortical carcinoma with intracaval extension. J Urol. 1997;158:2056–61.PubMedCrossRefGoogle Scholar
  28. 28.
    Krebs TL, Wagner BJ. MR imaging of adrenal gland: radiologic pathologic correlation. Radiographics. 1998;18:1425–40.PubMedGoogle Scholar
  29. 29.
    Wilms G, Baert A, Marchal G, Goddeeris P. Computed tomography of the normal adrenal glands: correlative study with autopsy specimens. J Comput Assist Tomogr. 1979;3:467–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Johnson PT, Horton KM, Fishman EK. Adrenal imaging with MDCT: nonneoplastic disease. AJR Am J Roentgenol. 2009;193:1128–35.PubMedCrossRefGoogle Scholar
  31. 31.
    Lee MJ, Hahn PF, Papanicolaou N, et al. Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. Radiology. 1991;179:415–8.PubMedGoogle Scholar
  32. 32.
    Boland GW, Lee MJ, Gazelle GS, et al. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171:201–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Boland GW, Blake MA, Hahn PF, Mayo-Smith WW. Incidental adrenal lesions: principles, techniques and algorithms for imaging characterization. Radiology. 2008;249:756–75.PubMedCrossRefGoogle Scholar
  34. 34.
    Haider MA, Ghai S, Jhaveri K, Lockwood G. Chemical shift MR imaging of hyperattenuating (> 10 HU) adrenal masses: does it still have a role? Radiology. 2004;231:711–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics. 2001;21:995–1012.PubMedGoogle Scholar
  36. 36.
    Hricak H, Husband J, Panicek DM. Oncologic imaging: essentials of reporting common cancers. Philadelphia: Saunders/Elsevier; 2007.Google Scholar
  37. 37.
    Blake MA, Cronin CG, Boland GW. Adrenal imaging. AJR Am J Roentgenol. 2010;194:1450–60.PubMedCrossRefGoogle Scholar
  38. 38.
    Caoili EM, Korobkin M, Francis IR, et al. Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol. 2000;175:1411–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Park BK, Kim CK, Kim B, Lee JH. Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses. Radiology. 2007;243:760–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Guo YK, Yang ZG, Li Y, et al. Uncommon adrenal masses: CT and MRI features with histopathologic correlation. Eur J Radiol. 2007;62:359–70.PubMedCrossRefGoogle Scholar
  41. 41.
    Kawashima A, Sandler CM, Ernst RD. Imaging of nontraumatic hemorrhage of the adrenal gland. Radiographics. 1999;19:949–63.PubMedGoogle Scholar
  42. 42.
    Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011;18:R253–76.PubMedCrossRefGoogle Scholar
  43. 43.
    Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc. 1999;74:543–52.PubMedCrossRefGoogle Scholar
  44. 44.
    Yun M, Kim W, Alnafisi N, et al. 18 F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001;42:1795–9.PubMedGoogle Scholar
  45. 45.
    Shulkin BL, Thompson NW, Shapiro B, et al. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology. 1999;212:35–41.PubMedGoogle Scholar
  46. 46.
    Wong KK, Arabi M, Bou-Assaly W, et al. Evaluation of incidentally discovered adrenal masses with PET and PET/CT. Eur J Radiol. 2012;81:441–50.PubMedCrossRefGoogle Scholar
  47. 47.
    Gross MD, Gauger PG, Djekidel M, Rubello D. The role of PET in the surgical approach to adrenal disease. Eur J Surg Oncol. 2009;35:1137–45.PubMedCrossRefGoogle Scholar
  48. 48.
    Imani F, Agopian VG, Auerbach MS, et al. 18 F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50:513–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Win Z, Al-Nahhas A, Towey D, et al. 68 Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun. 2007;28:359–63.PubMedCrossRefGoogle Scholar
  50. 50.
    Naji M, Zhao C, Welsh SJ, et al. 68 Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13:769–75.PubMedCrossRefGoogle Scholar
  51. 51.
    Sohaib SA, Hanson JA, Newell-Price JD, et al. CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing’s syndrome. AJR Am J Roentgenol. 1999;172:997–1002.PubMedCrossRefGoogle Scholar
  52. 52.
    Rozenblit A, Morehouse HT, Amis ES. Cystic adrenal lesions: CT features. Radiology. 1996;201:541–8.PubMedGoogle Scholar
  53. 53.
    Asbeshouse GA, Goldstein RB, Asbeshouse BS. Adrenal cysts: review of literature and report of three cases. J Urol. 1959;81:711–9.Google Scholar
  54. 54.
    Peppercorn PD, Reznek RH. State-of-the-art CT and MRI of the adrenal gland. Eur Radiol. 1997;7:822–36.PubMedCrossRefGoogle Scholar
  55. 55.
    Burks DW, Mirvis SE, Shanmuganathan K. Acute adrenal injury after blunt abdominal trauma: CT findings. AJR Am J Roentgenol. 1992;158:503–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Swift DL, Lingeman JE, Baum WC. Spontaneous retroperitoneal hemorrhage: a diagnostic challenge. J Urol. 1980;123:577–82.PubMedGoogle Scholar
  57. 57.
    Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer. 1950;3:74–85.PubMedCrossRefGoogle Scholar
  58. 58.
    Tsushima Y, Takahashi-Taketomi A, Endo K. Diagnostic utility of diffusion-weighted MR imaging and apparent diffusion coefficient value for the diagnosis of adrenal tumors. J Magn Reson Imaging. 2009;29:112–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Fishman EK, Deutch BM, Hartman DS, et al. Primary adrenocortical carcinoma: CT evaluation with clinical correlation. AJR Am J Roentgenol. 1987;148:531–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Hussain S, Belldegrun A, Seltzer SE, et al. Differentiation of malignant from benign adrenal masses: predictive indices on computed tomography. AJR Am J Roentgenol. 1985;144:61–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Faria JF, Goldman SM, Szejnfeld J, et al. Adrenal masses: characterization with in vivo proton MR spectroscopy–initial experience. Radiology. 2007;245:788–97.PubMedCrossRefGoogle Scholar
  62. 62.
    Chiche L, Dousset B, Kieffer E, Chapuis Y. Adreno-cortical carcinoma extending into the inferior vena cava: presentation of a 15-­patient series and review of the literature. Surgery. 2006;139:15–27.PubMedCrossRefGoogle Scholar
  63. 63.
    Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol. 2011;60:1055–65.PubMedCrossRefGoogle Scholar
  64. 64.
    Reibetanz J, Jurowich C, Erdogan I, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255:363–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol. 2010;57:873–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Porpiglia F, Miller BS, Manfredi M, et al. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer. 2011;2:372–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:4501–4.PubMedCrossRefGoogle Scholar
  68. 68.
    Polat B, Fassnacht M, Pfreundner L, et al. Radiotherapy in adrenocortical carcinoma. Cancer. 2009;115:2816–23.PubMedCrossRefGoogle Scholar
  69. 69.
    Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005;6:386–94.PubMedGoogle Scholar
  70. 70.
    Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003;169:5–11.PubMedCrossRefGoogle Scholar
  71. 71.
    Pommier RF, Brennan MF. Management of adrenal neoplasms. Curr Probl Surg. 1991;28:657–739.PubMedCrossRefGoogle Scholar
  72. 72.
    Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics. 2010;30:269–91.PubMedCrossRefGoogle Scholar
  73. 73.
    Paling MR, Willimason BRJ. Adrenal involvement in non-hodgkins lymphoma. AJR Am J Roentgenol. 1983;141:303–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Mester U, Goor O, Lerman H, et al. PET–CT of extranodal lymphoma. AJR Am J Roentgenol. 2004;182:1579–86.CrossRefGoogle Scholar
  75. 75.
    Blake MA, Prakash P, Cronin CG. PET/CT for adrenal assessment. AJR Am J Roentgenol. 2010;195:W91–5.PubMedCrossRefGoogle Scholar
  76. 76.
    Mester U, Miller E, Lerman H, et al. 18 F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med. 2006;47:32–7.Google Scholar
  77. 77.
    Boland GW, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology. 2011;259:117–26.PubMedCrossRefGoogle Scholar
  78. 78.
    Blake MA, Slattery JM, Kalra MK, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy—initial experience. Radiology. 2006;238:970–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Perri M, Erba P, Volterrani D, et al. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. AJR Am J Roentgenol. 2011;197:209–16.PubMedCrossRefGoogle Scholar
  80. 80.
    Chong S, Lee KS, Kim HY, et al. Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. Radiographics. 2006;26:1811–24.PubMedCrossRefGoogle Scholar
  81. 81.
    Otal P, Escourrou G, Mazerolles C, et al. Imaging features of uncommon adrenal masses with histopathologic correlation. Radiographics. 1999;19:569–81.PubMedGoogle Scholar
  82. 82.
    Schwartz LH, Macari M, Huvos AG, Panicek DM. Collision tumors of the adrenal gland: demonstration and characterization at MR imaging. Radiology. 1996;201:757–60.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of RadiologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations